Spyre Therapeutics, Inc. (SYRE) Misses Q3 EPS by 54c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q3 EPS of ($1.36), $0.54 worse than the analyst estimate of ($0.82).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
• CVS Health (CVS) PT Raised to $110 at BofA Securities
• Devon Energy (DVN) PT Lowered to $67 at Wolfe Research: Activist Toms interest positive